Did Remi Bader confirm she used Ozempic?

Yes. Bader publicly confirmed Ozempic use in interviews. She discussed both the medication and her decision to stop taking it.

Is it normal to regain weight after stopping Ozempic or Wegovy?

Yes. The STEP 1 extension trial showed participants regained roughly two-thirds of lost weight within one year of discontinuation. This is consistent with the understanding that GLP-1 receptor agonists manage obesity while active but do not cure the underlying metabolic condition.

Why did Remi Bader choose bariatric surgery after Ozempic?

Bader described the decision publicly as a response to the weight regain she experienced after stopping Ozempic. She has not disclosed all of her medical reasoning, and the HealthRX Medical Team respects that boundary.

Can you prevent weight regain after stopping a GLP-1 drug?

Complete prevention is unlikely based on current evidence. Lifestyle modifications (resistance training, high-protein diet, behavioral support) may slow the rate of regain but have not been shown to fully counteract the neurohormonal rebound. Most clinical guidelines now recommend indefinite GLP-1 therapy for patients who respond, rather than planned discontinuation.

Is Ozempic approved for weight loss?

Ozempic is FDA-approved for type 2 diabetes. Its active ingredient, semaglutide, is approved for weight management under the brand name Wegovy at a higher dose (2.4 mg weekly versus Ozempic's maximum of 2 mg). Many physicians prescribe Ozempic off-label for weight loss.

Remi Bader Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Why the HealthRX Medical Team Is Covering This Story

Remi Bader's experience is not gossip. It is a publicly documented, self-disclosed medical timeline that maps almost exactly onto the discontinuation data from the STEP 1 trial extension. When a public figure with millions of followers walks through GLP-1 initiation, cessation, rebound weight gain, and then bariatric surgery on camera, the clinical teaching opportunity is enormous.

This page treats Bader's own public statements as primary sources and layers peer-reviewed evidence onto each phase. Where the public record is ambiguous, we say so.

At a glance

Drug disclosed: Ozempic (semaglutide 0.5 mg / 1 mg subcutaneous injection, approved for type 2 diabetes; widely prescribed off-label for weight management)
Status: Confirmed use and confirmed discontinuation, per Bader's own public interviews
Key outcome: Significant, rapid weight regain after stopping
Subsequent intervention: Bariatric surgery (publicly disclosed)
Clinical parallel: STEP 1 extension data showing two-thirds of lost weight regained within one year of semaglutide discontinuation

Phase 1: Pre-Ozempic Public Profile

Remi Bader rose to prominence as a plus-size fashion influencer on TikTok, known for her "realistic haul" try-on videos that routinely drew tens of millions of views. Her content centered on body acceptance and honest reactions to how clothing fits across a range of sizes.

Before disclosing any medication use, Bader built a brand on transparency about her body. That transparency would later extend to her medical decisions, making her timeline unusually well-documented compared to most celebrity medication disclosures.

Phase 2: Confirmed Ozempic Use

Bader confirmed publicly that she had used Ozempic. In interviews, she described being prescribed the medication and using it for a period before discontinuing. She did not describe the experience as positive overall, and her public statements focused heavily on what happened after she stopped.

Clinical context for this phase. Ozempic (semaglutide) is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes at doses of 0.5 mg, 1 mg, and 2 mg weekly. Its use for weight management in patients without diabetes is off-label. The weight-loss-specific formulation, Wegovy, delivers semaglutide at 2.4 mg weekly, but many patients have been prescribed Ozempic for weight loss at lower doses.

Semaglutide works by mimicking GLP-1, a gut hormone that slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves insulin sensitivity. In the STEP 1 trial, participants on 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo.

The HealthRX Medical Team notes that at the Ozempic dose range (0.5 to 1 mg), weight loss is typically more modest than what the STEP trials reported at the 2.4 mg Wegovy dose. Patients prescribed Ozempic off-label for obesity may not achieve the same magnitude of effect.

Phase 3: Discontinuation and Documented Weight Regain

This is the phase that made Bader's story clinically significant. After stopping Ozempic, she publicly described gaining back more weight than she had lost. In a 2023 interview, she stated that the rebound was rapid and distressing. Multiple media outlets, including People and other entertainment publications, documented her statements about the experience.

Bader has been candid that the weight regain was not simply a return to baseline. She described gaining beyond her pre-medication weight, a pattern that some patients report anecdotally, though clinical trial data on "overshoot" remains limited.

Clinical context for this phase. The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, followed participants for one year after semaglutide withdrawal. The findings were striking: participants regained approximately two-thirds of their prior weight loss within 52 weeks of stopping. Cardiometabolic improvements (blood pressure, lipids, HbA1c) also reversed.

Why does this happen? GLP-1 receptor agonists suppress appetite through central and peripheral mechanisms, but they do not permanently reset the body's weight "set point." Research published in The New England Journal of Medicine has shown that the neurohormonal adaptations that defend body weight, including increased ghrelin, decreased leptin, and reduced energy expenditure, reassert themselves when the drug is removed. The body, in effect, is still metabolically programmed to return to its higher weight.

The HealthRX Medical Team emphasizes that Bader's rebound is not a failure of willpower. It is a predictable physiological response. GLP-1 medications are increasingly understood as chronic therapies, similar to blood pressure medications: they work while you take them, and the condition returns when you stop. The American Gastroenterological Association and the Endocrine Society both now frame obesity pharmacotherapy as long-term treatment, not a short course.

Whether Bader experienced true "overshoot" (regaining past her original weight) versus returning to the trajectory her weight was already on is impossible to determine from public information alone. Some researchers hypothesize that the appetite suppression of GLP-1 drugs may lead to muscle mass loss during the weight loss phase, which could reduce resting metabolic rate and predispose to regain beyond baseline. A 2024 study in JAMA Network Open found that approximately 40% of weight lost on semaglutide was lean mass, a ratio that raises questions about body composition during and after treatment.

Phase 4: Bariatric Surgery

Bader subsequently disclosed that she underwent bariatric surgery. She shared this decision publicly, framing it as a step she took after the GLP-1 experience did not produce a lasting result.

Clinical context for this phase. Bariatric surgery (including sleeve gastrectomy and Roux-en-Y gastric bypass) remains the most durable intervention for severe obesity. A long-term follow-up study published in The Lancet demonstrated that bariatric surgery maintains significant weight loss at 10 and even 20 years, with sustained improvements in type 2 diabetes remission, cardiovascular risk, and mortality.

The mechanisms differ from GLP-1 drugs. Surgery physically alters the gastrointestinal tract, which changes bile acid signaling, gut hormone profiles (including a sustained increase in endogenous GLP-1), and the gut microbiome. These changes appear more durable than exogenous GLP-1 administration because they are structural, not pharmacological.

The HealthRX Medical Team points out that Bader's progression from GLP-1 medication to bariatric surgery is not uncommon. A growing number of patients try pharmacotherapy first and turn to surgery when the medication proves unsustainable, whether due to side effects, cost, insurance coverage gaps, or rebound upon discontinuation. The American Society for Metabolic and Bariatric Surgery has noted increased patient inquiries following the GLP-1 medication wave, including from patients who experienced weight regain after stopping.

What Bader's Timeline Teaches About GLP-1 Prescribing

Three clinical lessons emerge from the public record.

First, GLP-1 medications require long-term commitment. The evidence is now clear. The FDA label for Wegovy does not specify a treatment duration endpoint, and clinical guidelines treat these drugs as indefinite therapy for patients who respond. Prescribers who frame GLP-1 medications as a short course are setting patients up for the exact experience Bader described.

Second, discontinuation counseling is essential. Patients starting GLP-1 therapy deserve an honest conversation about what happens if they stop. The STEP 1 extension data should be part of informed consent. Bader has said publicly that she did not feel adequately prepared for the rebound.

Third, body composition monitoring matters. If a significant portion of weight lost on GLP-1 drugs is lean mass, then resistance training and adequate protein intake during treatment are not optional add-ons. They are medically necessary to preserve metabolic rate and functional capacity. The HealthRX Medical Team recommends that any patient on GLP-1 therapy for weight loss undergo periodic body composition assessment (DEXA or bioimpedance) and follow a structured resistance exercise program with protein intake of at least 1.2 g/kg/day.

What the Public Record Does Not Tell Us

Bader has been unusually open, but there are boundaries to what is publicly known. Her specific Ozempic dosage, duration of use, whether she trialed the higher 2.4 mg Wegovy dose, the type of bariatric surgery she underwent, and her current medication regimen have not all been confirmed in public statements. Speculation about these details would be irresponsible, and the HealthRX Medical Team declines to fill those gaps with conjecture.

Frequently asked questions

›

References

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity. Endocrine Society
FDA Prescribing Information for Wegovy (semaglutide). FDA
Long-term outcomes of bariatric surgery. The Lancet. 2023. The Lancet
Protein intake recommendations during GLP-1 therapy for lean mass preservation. PubMed
Body composition changes during semaglutide treatment. JAMA Network Open. 2024. JAMA Network Open